Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2018.
Commission
File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation
of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ]
Form 40-F [
]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ___
Note: Regulation S-T Rule 101(b)(1) only permits the
submission in paper of a Form 6-K if submitted solely to provide an
attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ___
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant's “home
country”), or under the
rules of the home country exchange on which the registrant's
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibit 99.1 and shall be incorporated by reference into the
Company's effective Registration Statements on Form F-3, as amended
and supplemented (Registration Statement Nos. 333-172796 and
333-218297), filed with the Securities and Exchange Commission,
from the date on which this Report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished
by Intellipharmaceutics International Inc. under the Securities Act
of 1933 or the Securities Exchange Act of 1934.
Intellipharmaceutics International Inc. (the
“Company”) announced today that it has received a
letter from Nasdaq Listing Qualifications notifying the Company
that it had regained compliance with Nasdaq’s minimum bid
price requirement. The letter noted that as of September 28, 2018,
the Company evidenced a closing bid price of its common shares in
excess of the $1.00 minimum requirement for at least ten
consecutive business days. Separately, the Company received
notification from the Hearings Advisor from the Nasdaq Office of
General Counsel, informing the Company that the Nasdaq Hearings
Panel has granted its request for continued listing through October
17, 2018 while the Company works to regain compliance with
Nasdaq’s $2.5 million stockholders’ equity continued
listing requirement. A copy of the press release is attached
as Exhibit 99.1 to this report and is incorporated herein by
reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew Patient
|
|
Date:
October 1, 2018
|
Andrew
Patient
Chief Financial Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
News
Release dated October 1, 2018 – Intellipharmaceutics Regains
Compliance with Nasdaq Minimum Bid Price Requirement and Receives
Requested Extension from Nasdaq Panel
|